Patients with advanced HCC
Conditions
Interventions
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with advanced HCC with pathological or clinical diagnosis; 2. Subjects aged 18-75 years, with no gender limit; 3. Child Pugh class a subjects; 4. The subjects voluntarily agreed to participate in the observation and could cooperate closely in the treatment observation; the subjects themselves or their entrusted agents agreed and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients whose survival time is expected to be less than 6 months; 2. Patients undergoing systemic chemotherapy and immunotherapy; 3. Patients with high fever and various local or systemic severe infections (including respiratory tract, urogenital system, digestive system, septicemia, etc.); 4. Patients with language disorder and unable to express their wishes; 5. Patients with uncontrollable hypertension, heart and lung failure, thrombophlebitis, severe bleeding tendency and risk of massive bleeding (esophageal varices with bleeding history); 6. Patients with serious heart, brain, liver, kidney, hematopoietic system, endocrine system problems, or mental illness; those who participated in other clinical trials within 2 weeks before enrollment; 7. Patients who had received immunotherapy within 4 weeks before enrollment; those who suspected or had a history of alcohol and drug abuse; patients with active infectious diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis, and connective tissue diseases; 8. Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A total of 75 immune cell markers were detected and differential indicators were selected.; | — |
Countries
China
Contacts
Public ContactDuanming Du
Shenzhen Second People's Hospital
Outcome results
None listed